What’s Happening to the Share Price of Immuron Ltd?

What’s Happening to the Share Price of Immuron Ltd?

What does Immuron Ltd do?

Immuron Ltd [ASX:IMC] is a company developing medications for gut related and liver diseases.

Their product, Travelan, reduces the risk of traveller’s diarrhoea, preventing it before it even starts. Which has recently had a successful launch in the US.

They are also developing products for NASH (non-alcoholic liver disease) and ASH, (alcoholic liver disease).

The major feature of NASH is inflamed fatty liver, which can lead to cirrhosis, just like alcoholic liver disease. It causes permanent liver damage and is caused mainly by poor diet and sedentary lifestyle.

Their product is an oral medication which operates in the gut and does not enter the bloodstream, which improves liver function and reduces inflammation.

If these trials are successful, there is a huge global market, as liver disease is forecast by some to be the next global epidemic.

That’s interesting but what is the chart telling us?

What does the chart look like?

I find it helpful to bring up a chart. Here is the daily chart of IMC.

Immuron graph

Source: STEX

The chart seems to be indicating recent interest in this company. It’s a company you could perhaps follow; just keep one eye on it.

What now for IMC shares?

The company is on an investor road show in the US. That may explain recent market action, but it’s a company you could follow now. See if it makes any further share price moves

Also, the chart shows this company is lightly traded, so you need to apply a little risk management in that regard.

To find out exactly where you can find stocks like these, go here.
Terence Duffy,
Research Analyst, Cycles, Trends and Forecasts

Join Markets and Money on Google+

Leave a Reply

Be the First to Comment!

Notify of
Letters will be edited for clarity, punctuation, spelling and length. Abusive or off-topic comments will not be posted. We will not post all comments.
If you would prefer to email the editor, you can do so by sending an email to letters@marketsandmoney.com.au